# A Study Comparing the Plasma Drug Exposure of an Oral Dose of Palbociclib (PD-0332991) to an Intravenous Dose of Palbociclib (PD-0332991)

> **NCT01802476** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 14 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Oral Drug Formulation of PD-0332991
- **DRUG:** Intravenous Formulation of PD-0332991

## Key facts

- **NCT ID:** NCT01802476
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2013-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01802476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01802476, "A Study Comparing the Plasma Drug Exposure of an Oral Dose of Palbociclib (PD-0332991) to an Intravenous Dose of Palbociclib (PD-0332991)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01802476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*